Effects of APOE ε4 on brain amyloid, lacunar infarcts, and white matter lesions: Astudy among patients with subcortical vascular cognitive impairment

Neurobiology of Aging

Volumn 34, Issue 11, 2013, Pages 2482-2487

  Kim, Hee Jin ^a   Ye, Byoung Seok ^a   Yoon, Cindy W ^b   Cho, Hanna ^a   Noh, Young ^c   Kim, Geon Ha ^a,d   Choi, Yae Seul ^a   Kim, Jung Hyun ^a   Jeon, Seun ^e   Lee, Jong Min ^e   Kim, Jae Seung ^f   Choe, Yearn Seong ^a   Lee, Kyung Han ^a   Kim, Sung Tae ^a   Kim, Changsoo ^g   Kang, Dae Ryong ^g   Ki, Chang Seok ^a   Lee, Jae Hong ^f   Werring, David J ^h   Weiner, Michael W ⁱ   Na, Duk L ^a   Seo, Sang Won ^a   more..

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Inha University School of Medicine   (South Korea)

^c Gachon University   (South Korea)

^d Mokdong Hospital   (South Korea)

^e Hanyang University   (South Korea)

^f University of Ulsan College of Medicine   (South Korea)

^g Yonsei University College of Medicine   (South Korea)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Amyloid beta burden; APOE; Lacune; Subcortical vascular cognitive impairment; White matter hyperintensity

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; PITTSBURGH COMPOUND B;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN REGION; BRAIN SIZE; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HIGH RISK POPULATION; HUMAN; LACUNAR STROKE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN METABOLISM; SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT; WHITE MATTER LESION;

AMYLOID BETA BURDEN; APOE; LACUNE; SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT; WHITE MATTER HYPERINTENSITY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; APOLIPOPROTEIN E4; BRAIN; COGNITION DISORDERS; FEMALE; GENOTYPE; HUMANS; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NERVE FIBERS, MYELINATED; NEUROPSYCHOLOGICAL TESTS; PROSPECTIVE STUDIES; THIAZOLES; VASCULAR DISEASES;

EID: 84881547148     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2013.05.009     Document Type: Article

References (36)

1. Ahn H.J., Chin J., Park A., Lee B.H., Suh M.K., Seo S.W., Na D.L. Seoul Neuropsychological Screening Battery-dementia version (SNSB-D): a useful tool for assessing and monitoring cognitive impairments in dementia patients. J.Korean Med. Sci. 2010, 25:1071-1076.
2. Altamura C., Squitti R., Pasqualetti P., Tibuzzi F., Silvestrini M., Ventriglia M.C., Cassetta E., Rossini P.M., Vernieri F. What is the relationship among atherosclerosis markers, apolipoprotein E polymorphism and dementia?. Eur. J. Neurol. 2007, 14:679-682.
3. Amouyel P., Vidal O., Launay J.M., Laplanche J.L. The apolipoprotein E alleles as major susceptibility factors for Creutzfeldt-Jakob disease. The French Research Group on Epidemiology of Human Spongiform Encephalopathies. Lancet 1994, 344:1315-1318.
4. Chuang Y.F., Hayden K.M., Norton M.C., Tschanz J., Breitner J.C., Welsh-Bohmer K.A., Zandi P.P. Association between APOE epsilon4 allele and vascular dementia: the Cache County study. Dement. Geriatr. Cogn. Disord. 2010, 29:248-253.
5. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923.
6. Davidson Y., Gibbons L., Purandare N., Byrne J., Hardicre J., Wren J., Payton A., Pendleton N., Horan M., Burns A., Mann D.M. Apolipoprotein E epsilon4 allele frequency in vascular dementia. Dement. Geriatr. Cogn. Disord. 2006, 22:15-19.
7. Deb S., Braganza J., Norton N., Williams H., Kehoe P.G., Williams J., Owen M.J. APOE epsilon 4 influences the manifestation of Alzheimer's disease in adults with Down's syndrome. Br. J. Psychiatry 2000, 176:468-472.
8. Drzezga A., Grimmer T., Henriksen G., Muhlau M., Perneczky R., Miederer I., Praus C., Sorg C., Wohlschlager A., Riemenschneider M., Wester H.J., Foerstl H., Schwaiger M., Kurz A. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 2009, 72:1487-1494.
9. Erkinjuntti T., Inzitari D., Pantoni L., Wallin A., Scheltens P., Rockwood K., Roman G.C., Chui H., Desmond D.W. Research criteria for subcortical vascular dementia in clinical trials. J.Neur. Transm. Suppl. 2000, 59:23-30.
10. Fazekas F., Chawluk J.B., Alavi A., Hurtig H.I., Zimmerman R.A. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am. J. Roentgenol. 1987, 149:351-356.
11. Fazekas F., Strasser-Fuchs S., Kollegger H., Berger T., Kristoferitsch W., Schmidt H., Enzinger C., Schiefermeier M., Schwarz C., Kornek B., Reindl M., Huber K., Grass R., Wimmer G., Vass K., Pfeiffer K.H., Hartung H.P., Schmidt R. Apolipoprotein E epsilon 4 is associated with rapid progression of multiple sclerosis. Neurology 2001, 57:853-857.
12. Garcia-Alloza M., Gregory J., Kuchibhotla K.V., Fine S., Wei Y., Ayata C., Frosch M.P., Greenberg S.M., Bacskai B.J. Cerebrovascular lesions induce transient beta-amyloid deposition. Brain 2011, 134:3697-3707.
13. Graner M., Kahri J., Varpula M., Salonen R.M., Nyyssonen K., Jauhiainen M., Nieminen M.S., Syvanne M., Taskinen M.R. Apolipoprotein E polymorphism is associated with both carotid and coronary atherosclerosis in patients with coronary artery disease. Nutr. Metab. Cardiovasc. Dis. 2008, 18:271-277.
14. Harrington C.R., Louwagie J., Rossau R., Vanmechelen E., Perry R.H., Perry E.K., Xuereb J.H., Roth M., Wischik C.M. Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types. Significance for etiological theories of Alzheimer's disease. Am. J. Pathol. 1994, 145:1472-1484.
15. Hogh P., Oturai A., Schreiber K., Blinkenberg M., Jorgensen O.S., Ryder L., Paulson O.B., Sorensen P.S., Knudsen G.M. Apoliprotein E and multiple sclerosis: impact of the epsilon-4 allele on susceptibility, clinical type and progression rate. Mult. Scler. 2000, 6:226-230.
16. Hong Y.J., Yoon B., Shim Y.S., Cho A.H., Shin H.E., Kim Y.I., Kim S.Y., Yang D.W. APOE epsilon4 allele status in korean dementia patients with severe white matter hyperintensities. J.Alzheimers Dis. 2011, 24:519-524.
17. Jagust W.J., Zheng L., Harvey D.J., Mack W.J., Vinters H.V., Weiner M.W., Ellis W.G., Zarow C., Mungas D., Reed B.R., Kramer J.H., Schuff N., DeCarli C., Chui H.C. Neuropathological basis of magnetic resonance images in aging and dementia. Ann. Neurol. 2008, 63:72-80.
18. Kang Y., Na D.L. Seoul Neuropsychological Screening Battery 2003, Human Brain Research & Consulting Co., Incheon.
19. Katzman R., Galasko D.R., Saitoh T., Chen X., Pay M.M., Booth A., Thomas R.G. Apolipoprotein-epsilon4 and head trauma: synergistic or additive risks?. Neurology 1996, 46:889-891.
20. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergstrom M., Savitcheva I., Huang G.F., Estrada S., Ausen B., Debnath M.L., Barletta J., Price J.C., Sandell J., Lopresti B.J., Wall A., Koivisto P., Antoni G., Mathis C.A., Langstrom B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 2004, 55:306-319.
21. Lahoz C., Schaefer E.J., Cupples L.A., Wilson P.W., Levy D., Osgood D., Parpos S., Pedro-Botet J., Daly J.A., Ordovas J.M. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis 2001, 154:529-537.
22. Lawton M.P., Brody E.M. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969, 9:179-186.
23. Lee J.H., Kim S.H., Kim G.H., Seo S.W., Park H.K., Oh S.J., Kim J.S., Cheong H.K., Na D.L. Identification of pure subcortical vascular dementia using 11C-Pittsburgh compound B. Neurology 2011, 77:18-25.
24. Lim A., Tsuang D., Kukull W., Nochlin D., Leverenz J., McCormick W., Bowen J., Teri L., Thompson J., Peskind E.R., Raskind M., Larson E.B. Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series. J.Am. Geriatr. Soc. 1999, 47:564-569.
25. Martinez-Gonzalez N.A., Sudlow C.L. Effects of apolipoprotein E genotype on outcome after ischaemic stroke, intracerebral haemorrhage and subarachnoid haemorrhage. J.Neurol. Neurosurg. Psychiatry. 2006, 77:1329-1335.
26. Mayeux R., Ottman R., Maestre G., Ngai C., Tang M.X., Ginsberg H., Chun M., Tycko B., Shelanski M. Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer's disease. Neurology 1995, 45:555-557.
27. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
28. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 1999, 56:303-308.
29. Premkumar D.R., Cohen D.L., Hedera P., Friedland R.P., Kalaria R.N. Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. Am. J. Pathol. 1996, 148:2083-2095.
30. Rowe C.C., Ellis K.A., Rimajova M., Bourgeat P., Pike K.E., Jones G., Fripp J., Tochon-Danguy H., Morandeau L., O'Keefe G., Price R., Raniga P., Robins P., Acosta O., Lenzo N., Szoeke C., Salvado O., Head R., Martins R., Masters C.L., Ames D., Villemagne V.L. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol. Aging 2010, 31:1275-1283.
31. Seo S.W., Cho S.S., Park A., Chin J., Na D.L. Subcortical vascular versus amnestic mild cognitive impairment: comparison of cerebral glucose metabolism. J.Neuroimaging. 2009, 19:213-219.
32. Seo S.W., Im K., Lee J.M., Kim Y.H., Kim S.T., Kim S.Y., Yang D.W., Kim S.I., Cho Y.S., Na D.L. Cortical thickness in single- versus multiple-domain amnestic mild cognitive impairment. Neuroimage 2007, 36:289-297.
33. Sulkava R., Kainulainen K., Verkkoniemi A., Niinisto L., Sobel E., Davanipour Z., Polvikoski T., Haltia M., Kontula K. APOE alleles in Alzheimer's diseaseand vascular dementia in a population aged 85+. Neurobiol. Aging 1996, 17:373-376.
34. Tsuang D., Leverenz J.B., Lopez O.L., Hamilton R.L., Bennett D.A., Schneider J.A., Buchman A.S., Larson E.B., Crane P.K., Kaye J.A., Kramer P., Woltjer R., Trojanowski J.Q., Weintraub D., Chen-Plotkin A.S., Irwin D.J., Rick J., Schellenberg G.D., Watson G.S., Kukull W., Nelson P.T., Jicha G.A., Neltner J.H., Galasko D., Masliah E., Quinn J.F., Chung K.A., Yearout D., Mata I.F., Wan J.Y., Edwards K.L., Montine T.J., Zabetian C.P. APOE epsilon 4 Increases Risk for Dementia in Pure Synucleinopathies. Jama Neurol 2013, 70:223-228.
35. Wolk D.A., Price J.C., Saxton J.A., Snitz B.E., James J.A., Lopez O.L., Aizenstein H.J., Cohen A.D., Weissfeld L.A., Mathis C.A., Klunk W.E., De-Kosky S.T. Amyloid imaging in mild cognitive impairment subtypes. Ann. Neurol. 2009, 65:557-568.
36. Zetterberg H., Jacobsson J., Rosengren L., Blennow K., Andersen P.M. Association of APOE with age at onset of sporadic amyotrophic lateral sclerosis. JNeurol. Sci. 2008, 273:67-69.